🟩 Bariganix 180 mg
Generic Name: Ibrutinib
Brand Name: Bariganix
Strength: 180 mg
Dosage Form: Capsule
Manufacturer: Beacon Pharmaceuticals Ltd.
Category: Targeted Therapy | Oncology | Bruton's Tyrosine Kinase (BTK) Inhibitor
📌 Indications:
Bariganix (Ibrutinib) is indicated for the treatment of various B-cell malignancies, including:
-
Chronic Lymphocytic Leukemia (CLL)
-
Mantle Cell Lymphoma (MCL) (after at least one prior therapy)
-
Waldenström’s Macroglobulinemia (WM)
-
Marginal Zone Lymphoma (MZL) (after at least one anti-CD20-based therapy)
-
Chronic Graft-Versus-Host Disease (cGVHD) after failure of one or more systemic therapies
💊 Pharmacology:
Bariganix (Ibrutinib) is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that irreversibly binds to BTK. BTK plays a crucial role in B-cell receptor signaling and survival of malignant B-cells. Inhibiting BTK leads to reduced proliferation and increased apoptosis of abnormal B-cells, providing a highly targeted anti-cancer effect.
💉 Dosage & Administration:
-
CLL/SLL/WM: 420 mg orally once daily
-
MCL/MZL: 560 mg orally once daily
-
cGVHD: 420 mg orally once daily
-
Swallow whole with water. Do not open, break, or chew the capsule.
-
Dose may vary based on treatment plan or patient profile.
⚠️ Precautions & Warnings:
-
Bleeding risks – avoid use with anticoagulants/antiplatelets
-
Infections – monitor for bacterial, viral, or fungal infections
-
Atrial fibrillation and hypertension – monitor cardiac function
-
Tumor lysis syndrome – assess risk prior to initiation
-
Hepatotoxicity – monitor liver function tests
-
Cytopenias – regular blood count monitoring is essential
❌ Contraindications:
🤰 Pregnancy & Lactation:
⚕️ Side Effects:
Common:
-
Diarrhea
-
Fatigue
-
Nausea
-
Bruising
-
Muscle and joint pain
Serious:
-
Atrial fibrillation
-
Major hemorrhage
-
Infections (pneumonia, sepsis)
-
Cytopenias (neutropenia, anemia, thrombocytopenia)
🧊 Storage:
-
Store below 30°C in a dry place
-
Protect from moisture and direct sunlight
-
Keep out of reach of children